6201 - 6225 of 8816 Results
Title
Year
-
OPENTitle: Characterizing resting‐state networks in Parkinson’s disease: A multi‐aspect functional connectivity studyJournal Name: Brain and BehaviorPublisher: WileyVol: 11Issue #: 5Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/brb3.2101Best OA location URL: https://doi.org/10.1002/brb3.2101Citation Count: 13
-
OPENTitle: Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissueJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41467-021-27204-9Best OA location URL: https://escholarship.org/uc/item/0nc5b6htCitation Count: 42
- The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease2021OPENTitle: The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s diseaseJournal Name: BrainPublisher: Oxford University Press (OUP)Vol: 144Issue #: 10Start Page: 3114End Page: 3125Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1093/brain/awab191Best OA location URL: https://academic.oup.com/brain/article-pdf/144/10/3114/41381603/awab191.pdfCitation Count: 138
- Brain atrophy progression in Parkinson’s disease is shaped by connectivity and local vulnerability2021OPENTitle: Brain atrophy progression in Parkinson’s disease is shaped by connectivity and local vulnerabilityJournal Name: Brain CommunicationsPublisher: Oxford University Press (OUP)Vol: 3Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1093/braincomms/fcab269Best OA location URL: https://academic.oup.com/braincomms/article-pdf/3/4/fcab269/41729026/fcab269.pdfCitation Count: 48
-
OPENTitle: Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson’s Disease PatientsJournal Name: Frontiers in Molecular NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnmol.2021.763777Best OA location URL: https://doi.org/10.3389/fnmol.2021.763777Citation Count: 16
-
OPENTitle: Differential Effects of Pathological Beta Burst Dynamics Between Parkinson’s Disease Phenotypes Across Different MovementsJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 15Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2021.733203Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2021.733203/pdfCitation Count: 26
-
OPENTitle: Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adultsJournal Name: Neurological SciencesPublisher: Springer Science and Business Media LLCVol: 43Issue #: 5Start Page: 3079End Page: 3087Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s10072-021-05784-0Best OA location URL: https://link.springer.com/content/pdf/10.1007/s10072-021-05784-0.pdfCitation Count: 7
-
OPENTitle: A real-world study of wearable sensors in Parkinson’s diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-021-00248-wBest OA location URL: https://www.nature.com/articles/s41531-021-00248-w.pdfCitation Count: 47
- Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis2021OPENTitle: Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysisJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-021-00247-xBest OA location URL: https://www.nature.com/articles/s41531-021-00247-x.pdfCitation Count: 22
- Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease2021OPENTitle: Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-021-00250-2Best OA location URL: https://www.nature.com/articles/s41531-021-00250-2.pdfCitation Count: 15
-
OPENTitle: The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat ModelsJournal Name: BiomoleculesPublisher: MDPI AGVol: 11Issue #: 11Start Page: 1685End Page: 1685Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/biom11111685Best OA location URL: https://www.mdpi.com/2218-273X/11/11/1685/pdf?version=1636779345Citation Count: 7
-
OPENTitle: Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's DiseaseJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2021.729635Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2021.729635/pdfCitation Count: 15
- Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial2021OPENTitle: Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept TrialJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 10Start Page: 2408End Page: 2412Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28702Best OA location URL: https://doi.org/10.1002/mds.28702Citation Count: 16
- International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease2021OPENTitle: International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 11Start Page: 2583End Page: 2594Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28706Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.28706Citation Count: 106
-
OPENTitle: Mitochondrial Defects in Fibroblasts of Pathogenic MAPT PatientsJournal Name: Frontiers in Cell and Developmental BiologyPublisher: Frontiers Media SAVol: 9Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fcell.2021.765408Best OA location URL: https://doi.org/10.3389/fcell.2021.765408Citation Count: 5
-
OPENTitle: Stability Evaluation of Brain Changes in Parkinson's Disease Based on Machine LearningJournal Name: Frontiers in Computational NeurosciencePublisher: Frontiers Media SAVol: 15Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fncom.2021.735991Best OA location URL: https://www.frontiersin.org/articles/10.3389/fncom.2021.735991/pdfCitation Count: 9
-
OPENTitle: Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's diseaseJournal Name: Contemporary Clinical Trials CommunicationsPublisher: Elsevier BVVol: 24Issue #:Start Page: 100817End Page: 100817Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.conctc.2021.100817Best OA location URL: https://doi.org/10.1016/j.conctc.2021.100817Citation Count: 20
-
OPENTitle: Blood Neurofilament Light Chain in Parkinson’s Disease: Comparability between Parkinson’s Progression Markers Initiative (PPMI) and Asian CohortsJournal Name: Journal of Clinical MedicinePublisher: MDPI AGVol: 10Issue #: 21Start Page: 5085End Page: 5085Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/jcm10215085Best OA location URL: https://www.mdpi.com/2077-0383/10/21/5085/pdf?version=1635753758Citation Count: 12
-
OPENTitle: Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMIJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 7Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-021-00241-3Best OA location URL: https://www.nature.com/articles/s41531-021-00241-3.pdfCitation Count: 43
-
OPENTitle: Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?Journal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 22Issue #: 21Start Page: 11522End Page: 11522Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms222111522Best OA location URL: https://www.mdpi.com/1422-0067/22/21/11522/pdf?version=1635236511Citation Count: 10
-
OPENTitle: Kinetics of alpha-synuclein depletion in three brain regions following conditional pan-neuronal inactivation of the encoding gene (Snca) by tamoxifen-induced Cre-recombination in adult miceJournal Name: Transgenic ResearchPublisher: Springer Science and Business Media LLCVol: 30Issue #: 6Start Page: 867End Page: 873Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s11248-021-00286-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s11248-021-00286-3.pdfCitation Count: 3
-
OPENTitle: COVID-19 Vaccination Reactogenicity in Persons With Multiple SclerosisJournal Name: Neurology Neuroimmunology & NeuroinflammationPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1212/nxi.0000000000001104Best OA location URL: https://nn.neurology.org/content/nnn/9/1/e1104.full.pdfCitation Count: 37
-
OPENTitle: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s diseaseJournal Name: Acta Neuropathologica CommunicationsPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1186/s40478-021-01282-8Best OA location URL: https://actaneurocomms.biomedcentral.com/track/pdf/10.1186/s40478-021-01282-8Citation Count: 185
-
OPENTitle: Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label StudyJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 2Start Page: 693End Page: 709Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00251-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00251-6.pdfCitation Count: 23
-
OPENTitle: Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and DyskinesiaJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 2Start Page: 739End Page: 751Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-021-00256-1Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-021-00256-1.pdfCitation Count: 11